Otsuka Pharmaceuticals and Lundbeck's supplemental New Drug Application for the expanded labeling of ABILIFY MAINENA has been completed and will receive a substantive review by the U.S. Food and Drug Administration. Read More »
Biological Industries' Drug Master File for NutriStem hPSC XF Medium has been accepted by the U.S. Food and Drug Administration. Read More »
The U.S. Food and Drug Administration has approved Armodafinil Tablets developed by Lupin Pharmaceuticals. Read More »
Intarcia Therapeutics has submitted its New Drug Application (NDA) for ITCA 650 to the U.S. Food and Drug Administration. Read More »
AbbVie's oral poly polymerase inhibitor valiparib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »
Kedrion Biopharma and Kamada's Biologics License Application for human anti-rabies immunoglobulin therapy has been accepted for review by the U.S. Food and Drug Administration. Read More »
The Food and Drug Administration has approved Allergan's RESTASIS MULTIDOSE, its bottled version of RESTASIS, both of which are free of preservatives. Read More »
Astellas Pharma and Pfizer's joint-supplemental New Drug Application that will see the update of the XTANDI capsules product label has been approved by the Food and Drug Administration. Read More »
According to a new report released by the 2016 Generic Drug Savings and Access in the United States, generic prescription drugs generated 328 percent increase in annual savings since 2005. Read More »
Co-pay coupons and discounts offered to consumers ultimately will lead to higher costs across society as they increasingly drive up premiums, according to one leading expert on prescription drugs. Read More »
At first, price-slashing discount coupons for expensive drugs may appeal to consumers on an everyday basis, but a look behind the scenes suggests that using brand-name medications may possibly yield little, if any, net savings. Read More »
Alerts Sign-up
